Alteraciones de la coagulación en la COVID-19.

Published on Jan 1, 2020in Cirugia Y Cirujanos0.264
· DOI :10.24875/CIRU.20000416
Raúl Carrillo-Esper10
Estimated H-index: 10
Rebeca E Melgar-Bieberach2
Estimated H-index: 2
+ 2 AuthorsÁngela N Campa-Mendoza2
Estimated H-index: 2
Infection with the SARS-CoV-2 virus and the development of all manifestations of COVID-19, predisposes to arterial and venous thromboembolic disease. The coagulation system can be activated by various viruses, including SARS-CoV-2. Vascular endothelial damage, added to the development of disseminated intravascular coagulation, affects the prognosis and mortality from this disease. Treatment is aimed at the prevention, early detection and timely interventions of all coagulation disorders generated by COVID-19. The recommended anticoagulant is low molecular weight heparin, taking into account creatinine clearance, and if major invasive procedures will be performed, unfractionated heparin is a safe option.
Cited By1
#2Javier Mancilla-Galindo (UNAM: National Autonomous University of Mexico)H-Index: 3
Last. J de J Vidal-MayoH-Index: 1
view all 11 authors...
Conflicting results have been obtained through meta-analyses for the role of obesity as a risk factor for adverse outcomes in patients with coronavirus disease-2019 (COVID-19), possibly due to the inclusion of predominantly multimorbid patients with severe COVID-19. Here, we aimed to study obesity alone or in combination with other comorbidities as a risk factor for short-term all-cause mortality and other adverse outcomes in Mexican patients evaluated for suspected COVID-19 in ambulatory units ...
1 CitationsSource